FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if using a combination of fludarabine,
cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously
untreated chronic lymphocytic leukemia (CLL). The safety of this combination will also be
studied. This study will evaluate antibody-dependent cellular cytotoxicity (ADCC) and its
relationship to response.